ADIPONECTIN AND CARDIOVASCULAR RISK PREDICTION: STRATIFICATION OF CHEST PAIN PATIENTS BY A CLUSTER ANALYSIS

44 ABSTRACTS PRESENTED AT THE 10 TH INTERNATIONAL CONGRESS ON CORONARY ARTERY DISEASE, OCTOBER 13-16, 2013 RISK FACTORS AND DIABETES EUROPEAN CARDIOVASCULAR DISEASE STATISTICS: THE EUROPEAN HEART HEALTH II (EUROHEART II) PROJECT N. Townsend 1 , M. Nichols 2 , P. Scarborough 1 , M. Rayner 1 1 Public Health, University of Oxford, Oxford, United Kingdom 2 Faculty of Health, Deakin University, Geelong, Australia Background: European Cardiovascular Disease Statistics 2012, part of the EuroHeart II project, is the most recent update in a series of comprehensive Europe-wide reports on the mortality, morbidity, treatment, risk factors and costs of cardiovascular disease (CVD) in Europe. Methods: The report draws on international data sources that provide comparable data across the greatest number of European countries. The 53 member states of the WHO European region were included in the definition of Europe. In addition, a new cost of disease study was carried out to estimate the total costs (direct and indirect) of CVD in the EU. Results: Every year, CVD causes over 4 million deaths in Europe (47% of all deaths), and 1.9 million in the EU (40%). There are important inequalities between countries in mortality, morbidity, and in many risk factors that indicate the possible extent of the future burden. CVD is estimated to cost the EU almost EUR196 billion per year, of which 54% is due to direct costs to the health care system. Comparable data on incidence and prevalence of CVD are very limited, as are high quality data on important contributing risk factors, particularly diet and obesity. Conclusions: CVD remains the leading cause of death in Europe, and places a considerable burden on the health systems and economies of Europe. Further, the report highlights that there remain substantial gaps in the quality of data available to monitor and evaluate efforts to reduce CVD and CHD in Europe. No conflict of interest Downloaded by: 146.48.70.161 - 2/27/2015 3:17:22 PM 45 ABSTRACTS PRESENTED AT THE 10 TH INTERNATIONAL CONGRESS ON CORONARY ARTERY DISEASE, OCTOBER 13-16, 2013 RISK FACTORS AND DIABETES EFFECT OF FACTOR XIII POLYMORPHISMS ON THE RISK OF MYOCARDIAL INFARCTION Z. Bereczky 1 , Z.A. Mezei 1 , L. Balogh 2 , E. Katona 1 , E. Balogh 2 , I. Czuriga 2 , I. Édes 2 , L. Muszbek 3 1 Clinical Research Center, University of Debrecen Medical and Health Science Center, Debrecen, Hungary 2 Institute of Cardiology, University of Debrecen Medical and Health Science Center, Debrecen, Hungary 3 Clinical Research Center and Vascular Biology Thrombosis and Haemostasis Re- search Group of the Hungarian Academy of Sciences, University of Debrecen Medical and Health Science Center, Debrecen, Hungary Elevated factor XIII (FXIII) levels were demonstrated to be associated with increased risk of myocardial infarction (MI) in females, but not in males. Moreover, in our population FXIII-A Val34Leu polymorphism was protective against MI in patients with elevated fibrinogen levels. The role of FXIII-B subunit His95Arg and IntronK (nt29756C>G) polymorphisms in cardiovascular diseases has not been investigated, yet. In this study the above-mentioned polymorphisms were determined in 882 consecutive patients admitted for coronary angiography and in 1000 individuals representing the general Hungarian population. The rare allele frequencies of the His95Arg and IntronK (nt29756C>G) polymorphisms in the population were 0.08 and 0.15, respectively, which are similar to the results for Caucasians available in the HapMap database. The allele frequencies in the clinical controls (without MI and no significant coronary stenosis, n=276) did not differ significantly from the respective values in the general population. Individuals carrying the rare allele of FXIII-B IntronK poly